Intranasal desmopressin (DDAVP, DDVP, Minirin, Stimate Nasal Spray) is no longer indicated for primary nocturnal enuresis and is associated with an increased risk of severe hyponatremia (possibly ...
Nocturia is fairly prevalent. A review by Bosch and Weiss [3] noted that most older men and women experience at least 1 void per night and on average two thirds of patients experience 2 or more voids ...
The FDA has assigned a Prescription Drug User Fee Act target date of February 25, 2026 to the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ET-600 ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback